ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
05 August 2024 - 10:15PM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced the
appointment of Keith Lui as Senior Vice President of Commercial and
Medical Affairs.
“We are thrilled to welcome Keith to the ORIC
leadership team,” said Jacob M. Chacko, M.D., president and chief
executive officer. “Keith’s exceptional multi-decade track record
of helping to bring innovative therapies to market, combined with
his experience in strategic planning and medical affairs, will be
invaluable as we advance our differentiated pipeline of promising
oncology candidates into later-stage clinical development and
prepare for potential future commercialization to bring
transformative therapies to patients."
Mr. Lui brings over two decades of biopharma
experience focused on helping clinical-stage companies transition
to full commercialization. During his career, he has made
significant contributions to the strategic planning and commercial
launches of new medicines including Imbruvica®, Zelboraf®,
Pepaxto®, Posimir®, and multiple new indication launches for
blockbuster therapies such as Avastin® and Rituxan®. Most recently,
Mr. Lui was SVP, Business Development, Commercial and Medical
Affairs at DURECT, leading the preparation for commercialization,
and closing multiple licensing, co-marketing, and asset sale deals.
Prior to DURECT, he helped build the U.S. corporate infrastructure,
commercial function, and launch strategy at Oncopeptides. Prior to
that, he led commercial and launch-readiness efforts at Prothena
and Versartis and led the launch of Imbruvica at Pharmacyclics.
Earlier in his career, Mr. Lui held multiple oncology marketing and
sales roles at Genentech and Johnson & Johnson. He holds a BA
in integrative biology from the University of California, Berkeley,
and an MBA with distinction from Vanderbilt University.
“Having previously worked with several members
of the ORIC leadership team, I’m excited to join the company at
this pivotal inflection point,” said Mr. Lui. “With two programs
having reached early proof-of-concept, I look forward to working
with this extraordinary team to prepare for the potential start of
multiple registrational studies next year and the eventual
commercialization of innovative therapies that address cancer
resistance to improve patients’ lives.”
About ORIC Pharmaceuticals,
Inc. ORIC Pharmaceuticals is a clinical stage
biopharmaceutical company dedicated to improving patients’ lives
by Overcoming Resistance In Cancer. ORIC’s
clinical stage product candidates include (1) ORIC-114, a brain
penetrant inhibitor designed to selectively target EGFR and HER2
with high potency against exon 20 insertion mutations, being
developed across multiple genetically defined cancers, (2)
ORIC-944, an allosteric inhibitor of the polycomb repressive
complex 2 (PRC2) via the EED subunit, being developed for prostate
cancer, and (3) ORIC-533, an orally bioavailable small molecule
inhibitor of CD73, a key node in the adenosine pathway believed to
play a central role in resistance to chemotherapy- and
immunotherapy-based treatment regimens, being developed for
multiple myeloma. Beyond these three product candidates, ORIC® is
also developing multiple precision medicines targeting other
hallmark cancer resistance mechanisms. ORIC has offices in South
San Francisco and San Diego, California. For more information,
please go to www.oricpharma.com, and follow us
on X or LinkedIn.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements as that term is defined in Section 27A
of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements in this press release that are not
purely historical are forward-looking statements. Such
forward-looking statements include, among other things, statements
regarding target indications for ORIC’s product candidates; the
potential advantages of ORIC’s product candidates; plans underlying
ORIC’s clinical trials and development; and statements by the
company’s Chief Executive Officer and Senior Vice President of
Commercial and Medical Affairs. Words such as “believes,”
“anticipates,” “plans,” “expects,” “intends,” “will,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. The forward-looking statements
contained herein are based upon ORIC’s current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
projected in any forward-looking statements due to numerous risks
and uncertainties, including but not limited to: risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
operating as an early clinical stage company; ORIC’s ability to
develop, initiate or complete preclinical studies and clinical
trials for, obtain approvals for and commercialize any of its
product candidates; changes in ORIC’s plans to develop and
commercialize its product candidates; the potential for clinical
trials of ORIC’s product candidates to differ from preclinical,
initial, interim, preliminary or expected results; negative impacts
of health emergencies, economic instability or international
conflicts on ORIC’s operations, including clinical trials; the risk
of the occurrence of any event, change or other circumstance that
could give rise to the termination of ORIC’s license and
collaboration agreements; the potential market for ORIC’s product
candidates, and the progress and success of competing therapeutics
currently available or in development; ORIC’s ability to raise any
additional funding it will need to continue to pursue its business
and product development plans; regulatory developments in the
United States and foreign countries; ORIC’s reliance on third
parties, including contract manufacturers and contract research
organizations; ORIC’s ability to obtain and maintain intellectual
property protection for its product candidates; the loss of key
scientific or management personnel; competition in the industry in
which ORIC operates; general economic and market conditions; and
other risks. Information regarding the foregoing and additional
risks may be found in the section titled “Risk Factors” in ORIC’s
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (the “SEC”) on May 6, 2024, and ORIC’s future
reports to be filed with the SEC. These forward-looking statements
are made as of the date of this press release, and ORIC assumes no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in
the forward-looking statements, except as required by law.
Contact:Dominic Piscitelli,
Chief Financial
Officerdominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
Von Dez 2023 bis Dez 2024